featured
Clinical Benefit of Cemiplimab in Patients With Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
J Am Acad Dermatol 2023 Oct 13;[EPub Ahead of Print], AJ Stratigos, A Sekulic, K Peris, O Bechter, S Prey, KD Lewis, N Basset-Seguin, ALS Chang, S Dalle, A Fernandez Orland, L Licitra, C Robert, C Ulrich, A Hauschild, MR Migden, R Dummer, SY Yoo, E Okoye, I Bassukas, C Loquai, V De Giorgi, Z Eroglu, R Gutzmer, J Ulrich, S Puig, TJ Inocencio, CI Chen, PR LaFontaine, F Seebach, I Lowy, MG FuryFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.